Get started
Author

Chaiyut Charoentum

Observed names: C. Charoentum, Chaiyut CHAROENTUM, Charoentum, Chaiyut
ORCID: 0000-0001-8659-8629
Observed ORCID: 0000-0001-8659-8629
OpenAlex ID: A5087683383
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
2024 · B. Sangro, S.L. Chan, et al. · Annals of Oncology · 412
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
2018 · Sumanta K. Pal, Jonathan E. Rosenberg, et al. · Cancer Discovery · 263
Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
2005 · S. Thongprasert, S. Napapan, et al. · Annals of Oncology · 142
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
2024 · Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, et al. · Journal of Clinical Oncology · 111
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
2023 · Philip Clingan, Rahul Ladwa, et al. · Journal for ImmunoTherapy of Cancer · 63
PDF
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
2024 · Bruno Sangro, Peter R. Galle, et al. · Journal of Clinical Oncology · 62
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
2024 · L.-T. Chen, A. Vogel, et al. · ESMO Open · 40
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27
PDF
Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma
2007 · Chaiyut Charoentum, Sumitra Thongprasert, et al. · World Journal of Gastroenterology · 24
PDF
Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
2020 · Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, et al. · BMC Cancer · 18
PDF
Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus
2014 · Ann-Lii Cheng, Jin Li, et al. · Clinical Colorectal Cancer · 18
Stage-Specific Survival Rate of Breast Cancer Patients in Northern Thailand in Accordance with Two Different Staging Systems
2019 · Imjai Chitapanarux, Patumrat Sripan, et al. · Asian Pacific Journal of Cancer Prevention · 16
PDF
The Impact of a Multidisciplinary Team Conference on Non-Small Cell Lung Cancer Care: Time Barriers and Long-Term Outcomes
2024 · Somcharoen Saeteng, Busyamas Chewaskulyong, et al. · Journal of Clinical Medicine · 14
PDF
The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand
2023 · Wachiranun Sirikul, Nida Buawangpong, et al. · Cancers · 13
PDF
Cost‐effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non‐small cell lung cancer
2011 · Sumitra THONGPRASERT, Unchalee PERMSUWAN, et al. · Asia-Pacific Journal of Clinical Oncology · 10
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA
2024 · D. Nguyen, B. Besse, et al. · Journal of Thoracic Oncology · 9
PDF
Barriers to Immune Checkpoint Inhibitor Access for Patients With Cancer in Southeast Asia: Challenges and Policy Implications
2025 · Adrian E. Go, Frances Dominique V. Ho, et al. · JCO Global Oncology · 8
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
2025 · James Chih-Hsin Yang, Yuh-Min Chen, et al. · Clinical Lung Cancer · 7
Recurrence and death from breast cancer after complete treatments: an experience from hospitals in Northern Thailand.
2014 · Rungnapa Chairat, Adisom Puttisri, et al. · PubMed · 7
1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial
2020 · P. Clingan, D. Brungs, et al. · Annals of Oncology · 6
A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
2006 · Sumitra Thongprasert, Sirikul Soorraritchingchai, et al. · PubMed · 6
Dietary Counseling Outcomes in Patients with Lung Cancer in an Upper-Middle-Income Country: An Open-Label Randomized Controlled Trial
2024 · Busyamas Chewaskulyong, Haritchanan Malairungsakul, et al. · Journal of Clinical Medicine · 5
PDF
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
2022 · Athitaya Luangnara, Salin Kiratikanon, et al. · Frontiers in Immunology · 5
PDF
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
2022 · Bruno Sangro, Peter R Galle, et al. · Journal of Clinical Oncology · 5
Machine learning–based cfDNA fragmentation profiling using automated capillary electrophoresis for early detection of hepatocellular carcinoma
2026 · Sasimol Udomruk, Songphon Sutthitthasakul, et al. · Communications Medicine · 4
Works count: 86
Citation count: 1,349
H-index: 13
I10-index: 15
Year
Topic
Type